JOP20230098A1 - الأجسام المضادة لمستقبل Fc الوليدي (FcRn) وطرق استخدامها - Google Patents

الأجسام المضادة لمستقبل Fc الوليدي (FcRn) وطرق استخدامها

Info

Publication number
JOP20230098A1
JOP20230098A1 JOJO/P/2023/0098A JOP20230098A JOP20230098A1 JO P20230098 A1 JOP20230098 A1 JO P20230098A1 JO P20230098 A JOP20230098 A JO P20230098A JO P20230098 A1 JOP20230098 A1 JO P20230098A1
Authority
JO
Jordan
Prior art keywords
study participant
preventing
fcrn
antibodies
methods
Prior art date
Application number
JOJO/P/2023/0098A
Other languages
Arabic (ar)
English (en)
Inventor
Santiago Arroyo
Marie-Helene Jouvin
Jianhua Jin
William Denney
Hong Sun
Keith Karcher
Leona E Ling
Shawn Black
Sindhu Ramchandren
Yaowei Zhu
Jocelyn H Leu
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of JOP20230098A1 publication Critical patent/JOP20230098A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JOJO/P/2023/0098A 2020-11-06 2023-05-04 الأجسام المضادة لمستقبل Fc الوليدي (FcRn) وطرق استخدامها JOP20230098A1 (ar)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202063110884P 2020-11-06 2020-11-06
US202163137972P 2021-01-15 2021-01-15
US202163173126P 2021-04-09 2021-04-09
US202163173919P 2021-04-12 2021-04-12
US202163174423P 2021-04-13 2021-04-13
US202163175440P 2021-04-15 2021-04-15
US202163203075P 2021-07-07 2021-07-07
US202163203077P 2021-07-07 2021-07-07
US202163219155P 2021-07-07 2021-07-07
PCT/US2021/058188 WO2022098955A1 (en) 2020-11-06 2021-11-05 Fcrn antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
JOP20230098A1 true JOP20230098A1 (ar) 2023-05-04

Family

ID=81455198

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0098A JOP20230098A1 (ar) 2020-11-06 2023-05-04 الأجسام المضادة لمستقبل Fc الوليدي (FcRn) وطرق استخدامها

Country Status (12)

Country Link
US (1) US20220144946A1 (https=)
EP (1) EP4240417A4 (https=)
JP (1) JP2023548858A (https=)
KR (1) KR20230117575A (https=)
AU (1) AU2021376364A1 (https=)
CA (1) CA3200972A1 (https=)
IL (1) IL302516A (https=)
JO (1) JOP20230098A1 (https=)
MX (1) MX2023005313A (https=)
PH (1) PH12023551241A1 (https=)
TW (1) TW202233236A (https=)
WO (1) WO2022098955A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12240875B2 (en) 2017-12-08 2025-03-04 argenx BV Use of FCRN antagonists for treatment of generalized myasthenia gravis
KR102904658B1 (ko) 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
CA3101462A1 (en) 2018-06-08 2019-12-12 Argenx Bvba Compositions and methods for treating immune thrombocytopenia
KR102921210B1 (ko) 2018-07-20 2026-01-30 모멘타 파머슈티컬스 인코포레이티드 Fcrn 항체 조성물
BR112022013554A2 (pt) 2020-01-08 2022-09-06 argenx BV Métodos para tratar distúrbios do pênfigo
CA3258000A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE
EP4615481A1 (en) * 2022-11-07 2025-09-17 argenx BV Methods for treating lupus nephritis using fcrn antagonists
WO2024163894A1 (en) * 2023-02-04 2024-08-08 Momenta Pharmaceuticals, Inc. Compositions and methods for treating hemolytic disease of the fetus and newborn
TW202527982A (zh) * 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025163617A1 (en) * 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
WO2025186787A1 (en) * 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250052465A (ko) * 2015-01-30 2025-04-18 모멘타 파머슈티컬스 인코포레이티드 ＦｃＲｎ 항체 및 이의 사용 방법
CA3038894A1 (en) * 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
US12240875B2 (en) * 2017-12-08 2025-03-04 argenx BV Use of FCRN antagonists for treatment of generalized myasthenia gravis
KR102904658B1 (ko) * 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
MX2021000790A (es) * 2018-07-20 2021-07-21 Momenta Pharmaceuticals Inc Composiciones de anticuerpos del receptor neonatal para fc y metodos de uso de las mismas.
MA53903A (fr) * 2018-10-16 2021-08-25 UCB Biopharma SRL Méthode de traitement de la myasthénie grave
EP4007605A4 (en) * 2019-08-01 2023-08-16 Momenta Pharmaceuticals, Inc. ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
KR20230117575A (ko) 2023-08-08
CA3200972A1 (en) 2022-05-12
TW202233236A (zh) 2022-09-01
IL302516A (en) 2023-07-01
AU2021376364A9 (en) 2024-09-12
EP4240417A1 (en) 2023-09-13
MX2023005313A (es) 2023-07-11
PH12023551241A1 (en) 2023-11-20
AU2021376364A1 (en) 2023-06-22
WO2022098955A1 (en) 2022-05-12
US20220144946A1 (en) 2022-05-12
EP4240417A4 (en) 2024-10-02
WO2022098955A9 (en) 2022-06-09
JP2023548858A (ja) 2023-11-21

Similar Documents

Publication Publication Date Title
JOP20230098A1 (ar) الأجسام المضادة لمستقبل Fc الوليدي (FcRn) وطرق استخدامها
MX2022001380A (es) Anticuerpos de fcrn y metodos de uso de los mismos.
AU2018386193A8 (en) FcRn antibodies and methods of use thereof
EP4286011A3 (en) Fcrn antibodies and methods of use thereof
CR20210239A (es) Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
MX2021004270A (es) Anticuerpos estabilizadores de trem2.
BR112019001806A2 (pt) anticorpos para fcrn e métodos de uso dos mesmos
EA201990578A1 (ru) Связывающие молекулы, которые модулируют биологическую активность, проявляемую клеткой
EA201891656A1 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки для лечения аутоиммунных заболеваний
SA521420953B1 (ar) بروتين ربط مولد ضد مضاد لـمولد ضد ظهاري ذو 6 أغشية انتقالية من البروستاتا 1
NO20054170L (no) Antistoff mot human IL-21 reseptor og anvendelser derav
MX380702B (es) Proteinas de union al antigeno del receptor de oncostatina m.
JOP20200161A1 (ar) أجسام مضادة أحادية النسيلة وطرق استخدامها
EA201790961A1 (ru) Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения
JOP20210169B1 (ar) أجسام مضادة أحادية النسيلة ضد منطقة سلسلة بيتا من trbv9 بشري
AU2015255979B2 (en) Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses
EA201691482A1 (ru) Человеческие антитела к pd-1
JOP20230311A1 (ar) أجسام مضادة لـ sirp-ألفا
MX2021007093A (es) Anticuerpos btla.
JOP20210168B1 (ar) أجسام مضادة أحادية النسيلة ترتبط نوعيًا مع trbv9 بشري
MY202687A (en) Pharmaceutical chimeric receptor composition and method thereof
EA202092593A1 (ru) Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение
MX2022007855A (es) Anticuerpos hvem anti-humano (tnfrsf14) y usos de los mismos.